Spotlight: A development program can hit its milestones, advance scientifically and remain on schedule—and still underperform economically.
That distinction matters. Most R&D performance systems in Pharma and MedTech are very good at measuring progress: milestones achieved, timelines, clinical or technical success, regulatory advancement and pipeline movement.
But progress is not the same as value creation.
While an asset advances, its economics can change materially. Development costs rise. Timelines extend. Competitors move. Markets evolve. Differentiation narrows. New evidence changes risk and expected returns.
So perhaps the executive question should not only be: Are our R&D programs progressing? But also: Are we converting that progress into sufficient economic value?
In this post, “From Scientific Success to Economic Success: Rethinking How We Measure Pharma R&D Performance,” I explore how Pharma and MedTech leaders can complement traditional R&D KPIs with measures of value creation, risk-adjusted portfolio value, resource productivity and speed of learning.
Scientific success, development success and economic success are connected—but they are not interchangeable. And the metrics on the executive dashboard should make that distinction visible.
Checkout the full post below…
#Pharma #MedTech #RDStrategy #RDProductivity #PortfolioStrategy #LifeSciences
That distinction matters. Most R&D performance systems in Pharma and MedTech are very good at measuring progress: milestones achieved, timelines, clinical or technical success, regulatory advancement and pipeline movement.
But progress is not the same as value creation.
While an asset advances, its economics can change materially. Development costs rise. Timelines extend. Competitors move. Markets evolve. Differentiation narrows. New evidence changes risk and expected returns.
So perhaps the executive question should not only be: Are our R&D programs progressing? But also: Are we converting that progress into sufficient economic value?
In this post, “From Scientific Success to Economic Success: Rethinking How We Measure Pharma R&D Performance,” I explore how Pharma and MedTech leaders can complement traditional R&D KPIs with measures of value creation, risk-adjusted portfolio value, resource productivity and speed of learning.
Scientific success, development success and economic success are connected—but they are not interchangeable. And the metrics on the executive dashboard should make that distinction visible.
Checkout the full post below…
#Pharma #MedTech #RDStrategy #RDProductivity #PortfolioStrategy #LifeSciences
A molecule can meet its scientific objectives. A device can achieve its technical milestones. A development program can progress according to plan. And yet, the R&D portfolio may still underperform economically. That distinction is becoming increasingly important for Pharma and MedTech leaders.
R&D performance is traditionally viewed through measures such as milestone achievement, development timelines, technical or clinical success, regulatory progress, and pipeline advancement.
These metrics matter. But they largely answer one question: Are we successfully advancing our programs?
They do not necessarily answer the question that matters at an enterprise level, which is— Are we converting R&D investment into sufficient economic value?
That requires a broader view of performance.
An asset may continue to progress scientifically while its economics change significantly around it. Development costs increase. Timelines extend. The competitive landscape shifts. The addressable market evolves. Evidence changes the probability of success. Commercial differentiation narrows.
If our performance measures focus primarily on scientific and operational progress, these changes can remain disconnected from how R&D success is perceived and rewarded. This creates an important leadership challenge.
What if R&D performance were measured not only by progress, but by the quality of value creation?
That could mean complementing traditional R&D KPIs with measures that provide greater visibility into:
For executive teams facing increasing pressure on R&D returns, that distinction matters.
The opportunity may be to evolve from an R&D performance system that primarily measures activity and advancement to one that also measures the economic quality of those advances.
Because ultimately, a high-performing R&D organization should do more than move programs forward. It should consistently convert scientific innovation into sustainable enterprise value.
For Pharma and MedTech leadership teams reassessing R&D productivity, the starting question may therefore be surprisingly simple: Are the metrics on our executive dashboard telling us how R&D is performing—or only how R&D is progressing?
I help Pharma and MedTech leaders move beyond measuring R&D progress to managing R&D for value—connecting performance metrics, portfolio choices and resource allocation to stronger economic outcomes. If this is on your agenda, let’s talk.
R&D performance is traditionally viewed through measures such as milestone achievement, development timelines, technical or clinical success, regulatory progress, and pipeline advancement.
These metrics matter. But they largely answer one question: Are we successfully advancing our programs?
They do not necessarily answer the question that matters at an enterprise level, which is— Are we converting R&D investment into sufficient economic value?
That requires a broader view of performance.
An asset may continue to progress scientifically while its economics change significantly around it. Development costs increase. Timelines extend. The competitive landscape shifts. The addressable market evolves. Evidence changes the probability of success. Commercial differentiation narrows.
If our performance measures focus primarily on scientific and operational progress, these changes can remain disconnected from how R&D success is perceived and rewarded. This creates an important leadership challenge.
What if R&D performance were measured not only by progress, but by the quality of value creation?
That could mean complementing traditional R&D KPIs with measures that provide greater visibility into:
- value created relative to R&D investment;
- changes in risk-adjusted portfolio value;
- capital and resource productivity;
- speed of learning against critical investment assumptions; and
- the portfolio’s ability to redirect investment as evidence and economics evolve.
For executive teams facing increasing pressure on R&D returns, that distinction matters.
The opportunity may be to evolve from an R&D performance system that primarily measures activity and advancement to one that also measures the economic quality of those advances.
Because ultimately, a high-performing R&D organization should do more than move programs forward. It should consistently convert scientific innovation into sustainable enterprise value.
For Pharma and MedTech leadership teams reassessing R&D productivity, the starting question may therefore be surprisingly simple: Are the metrics on our executive dashboard telling us how R&D is performing—or only how R&D is progressing?
I help Pharma and MedTech leaders move beyond measuring R&D progress to managing R&D for value—connecting performance metrics, portfolio choices and resource allocation to stronger economic outcomes. If this is on your agenda, let’s talk.
Disclaimer: This article reflects observed industry trends and professional perspectives and does not constitute regulatory, legal, or operational advice. Read full disclaimer here.
About the author:
Dr. Shruti Bhat is an Advisor in Operational Excellence and Business Continuity Across Pharma and MedTech Value Chains (end-to-end).
Keywords and Tags:
#Pharma #MedTech #RDStrategy #RDProductivity #PortfolioStrategy #Innovation #LifeSciences
Categories: Operational Excellence | Life Science Industry | Pharma R&D
Follow Shruti on YouTube, LinkedIn
About the author:
Dr. Shruti Bhat is an Advisor in Operational Excellence and Business Continuity Across Pharma and MedTech Value Chains (end-to-end).
Keywords and Tags:
#Pharma #MedTech #RDStrategy #RDProductivity #PortfolioStrategy #Innovation #LifeSciences
Categories: Operational Excellence | Life Science Industry | Pharma R&D
Follow Shruti on YouTube, LinkedIn
Subscribe to Operational Excellence Academy YouTube channel: |  |
